HomeNDC LookupRxCUI directory › RxCUI 2735802

Etoposide 20 MG/ML Injectable Solution [Avopef] — RxCUI 2735802

RxNorm drug concept · Semantic branded drug
RxCUI 2735802 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2735802
Official nameEtoposide 20 MG/ML Injectable Solution [Avopef]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAvopef 20 MG/ML Injectable Solution; VP-16 20 MG/ML Injectable Solution [Avopef]
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Etoposide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Etoposide is a chemotherapy drug approved for two main cancers: small cell lung cancer and refractory testicular tumors — meaning testicular cancer that hasn't responded to other t...
  • What exactly is etoposide being used to treat in my case?
  • The most common things people experience are low blood counts — which means a higher risk of infection and bleeding — nausea, hair loss, fatigue, and appetite changes. Nausea is us...
  • What side effects should I actually expect?
📖 Read our full Etoposide guide →

🕸️ Concept Web — How Etoposide 20 MG/ML Injectable Solution [Avopef] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Etoposide 20 MG/ML Injectable Solution [Avopef] RxCUI 2735802

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Etoposide 4179
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Avopef 2735798
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Etoposide Injectable Solution 376890
    • Etoposide Injectable Product 1157928
    • Etoposide Injectable Solution [Avopef] 2735801
    • Avopef Injectable Product 2735800
    • Injectable Solution 316949
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Etoposide 20 MG/ML [Avopef] SBDC · 2735799
  • Etoposide Injectable Solution [Avopef] SBDF · 2735801
  • Avopef Injectable Product SBDG · 2735800
  • Avopef BN · 2735798

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2735802 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
83831-0144-05 1 VIAL in 1 CARTON (83831-144-05) / 5 mL in 1 VIAL Avopef Avyxa Pharma, LLC 2026-04-01
83831-0145-25 1 VIAL in 1 CARTON (83831-145-25) / 25 mL in 1 VIAL Avopef Avyxa Pharma, LLC 2026-06-24
Observed labelers: Avyxa Pharma, LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.